Canopy Growth (NYSE: CGC) stock price plunged more than 40% in the last three months alone. The steep share price selloff is supported by negative analyst’s reports along with lower than expected financial performance in the first quarter.
Canopy Growth stock price is currently trading around its 52-weeks low of $22 a share. Chief executive Mark Zekulin says investor’s reaction to the recent performance is fair, but he remains confident about Canopy’s prospects.
GMP Securities Analyst Ryan Macdonell has declined the target to C$45 from C$65. The analyst says lackluster performance highlights that Canopy has lost its leading market position in the recreational market. The return of C$6.4M oil and gel caps in the latest quarter indicates that the market is oversupplied, analyst claims.
Canopy Growth net revenue in the latest quarter increased 249% year over year. However, the revenues plunged 4% compared to the previous quarter. Its net revenue of $90 million missed analysts’ consensus estimate by $16 million.
The company is working on two priorities to offset negative sentiments.
First, the company is seeking to lay the foundation for creating a leadership position in the emerging industry. Consequently, the company plans to invest significantly in intellectual properties, building international reach, building brands and enhancing scaled production capability.
Second, the company is looking to generate sustainable revenue growth, high margins and big profits from Canadian markets.
Canopy’s dried cannabis sales in the first quarter increased 94% quarter over quarter in the Canadian recreational market.
The company has harvested 40,960 kilograms in Q1, representing an increase of 183% over Q4 2019. Moreover, its international medical cannabis revenue jumped 209% from the previous quarter.
The company has also filed 56 patent applications during the first quarter. This brings its patent portfolio to 111 patents and 270 patent applications.
The market analysts expect Canopy Growth stock price to remain under pressure. This is due to oversupply conditions both in recreational and medical markets. The increasing market competition could also add to headwinds.
Trusted & Regulated Stock & CFD Brokers
What we like
- 0% Fees on Stocks
- 5000+ Stocks, ETFs and other Markets
- Accepts Paypal Deposits
Min Deposit
$200
Charge per Trade
Zero Commission on real stocks
64 traders signed up today
Visit Now67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Available Assets
- Total Number of Stocks & Shares5000+
- US Stocks
- German Stocks
- UK Stocks
- European
- ETF Stocks
- IPO
- Funds
- Bonds
- Options
- Futures
- CFDs
- Crypto
Charge per Trade
- FTSE 100 Zero Commission
- NASDAQ Zero Commission
- DAX Zero Commission
- Facebook Zero Commission
- Alphabet Zero Commission
- Tesla Zero Commission
- Apple Zero Commission
- Microsoft Zero Commission
Deposit Method
- Wire Transfer
- Credit Cards
- Bank Account
- Paypall
- Skrill
- Neteller
What we like
- Sign up today and get $5 free
- Fractals Available
- Paypal Available
Min Deposit
$0
Charge per Trade
$1 to $9 PCM
Visit Now
Investing in financial markets carries risk, you have the potential to lose your total investment.
Available Assets
- Total Number of Shares999
- US Stocks
- German Stocks
- UK Stocks
- European Stocks
- EFTs
- IPOs
- Funds
- Bonds
- Options
- Futures
- CFDs
- Crypto
Charge per Trade
- FTSE 100 $1 - $9 per month
- NASDAQ $1 - $9 per month
- DAX $1 - $9 per month
- Facebook $1 - $9 per month
- Alphabet $1 - $9 per month
- Telsa $1 - $9 per month
- Apple $1 - $9 per month
- Microsoft $1 - $9 per month
Deposit Method
- Wire Transfer
- Credit Cards
- Bank Account
Share
Siraj Sarwar
